Skip to main
ARVN
ARVN logo

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 27%
Buy 41%
Hold 32%
Sell 0%
Strong Sell 0%

Bulls say

Arvinas Inc has showcased promising results in its clinical trials, particularly highlighting the statistically significant improvements in median progression-free survival (mPFS) for vepdegestrant (vepdeg) in ESR1 mutant populations, which offers a competitive edge compared to existing therapies. The Company's data suggests a potential for vepdeg to achieve over four months of mPFS, positioning it favorably against other treatments, and indicates a safe profile with no dose-limiting toxicities. With these advancements, Arvinas is well-poised for differentiation in the biopharmaceutical marketplace, underscoring its commitment to addressing unmet medical needs and enhancing patient outcomes.

Bears say

Arvinas Inc faces several challenges that contribute to a negative outlook on its stock. The lack of demonstrated benefit in the intention-to-treat population raises concerns about the potential for a restricted product label, which could hinder market differentiation and delay revenue generation. Additionally, significant competitive risks exist around both the approval timelines for its therapies and their ability to effectively compete against current and future treatments, further dampening investor confidence in the company's commercial prospects.

Arvinas Inc (ARVN) has been analyzed by 22 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 41% recommend Buy, 32% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 22 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.